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Abstract
Activation of innate immunity and deposition of blood-derived fibrin in the central nervous system 
(CNS) occur in autoimmune and neurodegenerative diseases, including multiple sclerosis (MS) 
and Alzheimer’s disease (AD). However, mechanisms linking blood-brain barrier (BBB) 
disruption with neurodegeneration are poorly understood, and exploration of fibrin as a therapeutic 
target has been limited by its beneficial clotting functions. Here we report the generation of 
monoclonal antibody 5B8 targeted against the cryptic fibrin epitope γ377–395 to selectively inhibit 
fibrin-induced inflammation and oxidative stress without interfering with clotting. 5B8 suppressed 
fibrin-induced nicotinamide adenine dinucleotide phosphate (NADPH) oxidase and 
proinflammatory gene expression. In animal models of MS and AD, 5B8 entered the CNS and 
bound to parenchymal fibrin, and its therapeutic administration reduced innate immune activation 
and neurodegeneration. Thus, fibrin-targeting immunotherapy inhibits autoimmune- and amyloid-
driven neurotoxicity and may have clinical benefit without globally suppressing innate immunity 
or interfering with coagulation in diverse neurological diseases.
Activation of innate immunity is a key feature of neurological diseases with different 
etiologies, including autoimmune and neurodegenerative CNS diseases1. Increasing 
evidence indicates that pathogenic activation of CNS innate immunity contributes to 
neuronal damage and modulates the onset and progression of neurodegenerative diseases2. 
Oxidative injury and release of free radicals have been proposed as common mechanisms for 
innate immune-driven neurodegeneration and demyelination in MS and AD3–6. Chronic 
innate immune activation and oxidative injury are key elements driving neurodegeneration in 
both relapsing-remitting– and progressive MS3,7,8. In progressive MS, there is robust 
microglia activation, oxidative stress, and neurodegeneration3,8,9. Pathogenic activation of 
innate immunity contributes to oxidative stress and cognitive decline in AD5. Little is known 
about the pathogenic signals that activate innate immune cells toward neurotoxic 
phenotypes. Understanding the mechanisms of activation of CNS innate immunity is 
essential for deciphering how neuroinflammation contributes to neuronal damage and for 
designing treatments for selective suppression of pathogenic functions of innate immunity.
Innate immune activation, blood-brain barrier (BBB) disruption, and fibrin deposition are 
intimately linked in neurological diseases10,11. The blood coagulation factor fibrinogen 
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extravasates into the CNS parenchyma upon BBB disruption and is converted to insoluble 
fibrin, a key proinflammatory matrix that activates innate immune responses11,12. 
Conversion of fibrinogen into fibrin exposes amino acids 377–395 in the fibrinogen γ chain 
(γ377–395) that bind to the CD11b I-domain of complement receptor 3 (CR3) (also known as 
CD11b/CD18, Mac-1, αMβ2) and induces microglia and macrophage activation13–16. Fibrin 
is deposited in AD and MS lesions at sites of microglial activation and macrophage 
infiltration (reviewed in11). Fibrin is detected in progressive MS and in active and chronic 
lesions (reviewed in11). In progressive MS, fibrin deposition in the cortex correlates with 
neuronal loss and inhibition of fibrinolysis17. BBB disruption and fibrin deposition occur 
also early in MS and precede demyelination18,19. Fibrinogen has been proposed as a 
cerebrospinal fluid and plasma biomarker for AD and mild cognitive impairment, and 
increased fibrinogen concentrations are considered a predictor of brain atrophy in AD 
(reviewed in11,20). Depletion of fibrin either genetically in fibrinogen deficient mice or by 
anticoagulants decreases neuroinflammation, demyelination, and axonal damage in animal 
models of MS and reduces microglia activation, white matter damage, and cognitive decline 
in animal models of AD (reviewed in11). Fibrin induces rapid and sustained microglia 
responses and macrophage infiltration into the CNS15,16. Although increased BBB 
disruption and fibrin deposition correlate with neurodegeneration, the molecular links 
between blood leakage into the CNS and neuronal damage are poorly understood. 
Furthermore, whether and how fibrin-induced activation of innate immunity is neurotoxic 
remains largely unknown.
Here we report an unanticipated role for fibrin as an activator of the NADPH oxidase 
complex that induced reactive oxygen species (ROS) release and innate immune-driven 
neurotoxicity in autoimmune and amyloid-driven neurodegeneration. Although innate 
immune activation is an attractive candidate for therapeutic intervention, selective therapies 
to inhibit neurotoxic effects of innate immune responses are not widely available. By 
targeting the γ377–395 cryptic fibrin epitope, we developed the first fibrin immunotherapy 
(monoclonal antibody 5B8) to selectively target the inflammatory form of fibrin without 
interfering with clotting or activation of innate immune cells by other ligands, such as 
lipopolysaccharide (LPS). 5B8 selectively bound to fibrin, but not soluble fibrinogen, and 
inhibited binding of fibrin to CR3 without interfering with fibrin polymerization, in vivo 
clotting time, or partial thromboplastin time (aPTT) in human plasma. 5B8 reduced NADPH 
oxidase activation, ROS release, microglial activation, and neurodegeneration in MS and AD 
animal models. These studies identify fibrin as a blood-derived signal that activates NADPH 
oxidase to promote innate immune-driven neurotoxicity, and identify fibrin-targeted 
immunotherapy as a novel therapeutic strategy to suppress innate immune-driven 
neurodegeneration at sites of increased vascular permeability without interfering with 
clotting or globally suppressing innate immunity.
Results
Design of fibrin-targeting immunotherapy.
The C- terminus of the fibrinogen γ chain contains two distinct non-overlapping sites at 
γ400–411 and γ377–395, which mediate platelet engagement and inflammation respectively 
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(Fig. 1a). Peptide γ400–411 is the binding site for the platelet αIIbβ3 integrin receptor and is 
required for platelet aggregation. Peptide γ377–395 is the binding site for the CD11b I-
domain of CD11b/CD1814 and is required for fibrin-induced activation of microglia and 
macrophages13,15,16. The γ377–395 binding site is considered “cryptic” in the soluble 
fibrinogen molecule and is exposed only upon conversion of fibrinogen to insoluble fibrin14 
(Fig. 1a). We hypothesized that monoclonal antibodies against γ377–395 would selectively 
recognize fibrin and inhibit fibrin’s interaction with the CD11b I-domain without affecting 
blood coagulation. To control for CD11b I-domain binding specificity, we also generated 
mouse monoclonal antibodies against the γ190–202 fibrin epitope, which is also cryptic, but 
is not required for binding to the CD11b I-domain14. Using a streamlined screening strategy, 
we selected monoclonal antibodies that selectively bind fibrin and inhibit microglia 
activation (Supplementary Fig. 1a). Antibodies 5B8, 4E11, and 4F1 had the highest 
selectivity and specificity for γ377–395, while anti-γ190–202 1E3 did not bind γ377–395, as 
expected (Fig. 1b, Supplementary Fig. 1b). To discriminate between fibrinogen and fibrin in 
biochemical and cellular assays, we developed an in vitro fibrin substrate that binds to 
recombinant CD11b I-domain more strongly than fibrinogen (Supplementary Fig. 1c), 
suggesting γ377–395 epitope exposure in vitro. All antibodies against cryptic epitopes bound 
with higher affinity to fibrin than to fibrinogen; among antibodies targeting γ377–395, 5B8 
bound fibrin to the greatest degree with minimal binding to soluble fibrinogen (Fig. 1c, 
Supplementary Fig. 1d). Competitive binding assays showed that 5B8 bound to human and 
mouse γ377–395 peptides, but not γ190–202 peptide (Supplementary Fig. 1e). 5B8 inhibited 
binding of the CD11b I-domain to fibrin (Fig. 1d), suggesting that 5B8 interferes with the 
ligand–receptor interaction.
Fibrin activates microglia, as evidenced by morphologic activation characterized by increase 
in cell size that is also associated with gene expression changes13,16. The morphologic 
activation assay, combined with automated quantification, was suitable for an unbiased and 
rapid comparison of multiple fibrin antibody clones in primary microglia cultures. Notably, 
among all antibodies generated against cryptic epitopes, only antibodies against γ377–395 
inhibited fibrin-induced morphologic activation of microglia; the highest inhibition (~87%) 
was by 5B8 (Supplementary Fig. 2a). The anti-γ190–202 1E3 antibody also bound fibrin but 
did not inhibit microglial activation (Supplementary Fig. 2a), suggesting that γ377–395 must 
be targeted to inhibit fibrin’s proinflammatory functions. The F(ab) fragment of 5B8 also 
inhibited fibrin-induced microglial activation (Supplementary Fig. 2b). 5B8 inhibited fibrin-
induced morphologic microglial activation in a concentration-dependent manner and 
reduced proinflammatory gene expression (Fig. 1e, Supplementary Fig. 2c,d). Isotype 
control IgG2b with endotoxin concentrations <0.002 EU/μg (Supplementary Figs. 2e) was 
used as control for all experiments in the study. 5B8 did not alter the polymerization time of 
fibrinogen to fibrin, did not inhibit activated aPTT in human plasma, and had no effect on 
murine plasma clotting time in vivo (Fig. 1f-h). ~80% of 5B8 was recovered 5 days after a 
single intraperitoneal (i.p.) injection into healthy wild-type mice (Supplementary Fig. 2f), 
suggesting that 5B8’s preferential binding to fibrin and minimal binding to soluble 
fibrinogen result in a minimal “sink-effect”.
In microglia and macrophages, fibrin induces proinflammatory gene expression associated 
with immune response and cell recruitment16. In bone marrow derived macrophages 
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(BMDMs), 5B8 reduced fibrin-induced transcriptional activation of genes related to immune 
cell migration, adhesion, inflammatory responses, regulation of T cell proliferation, and 
chemotaxis, as shown by whole-genome microarray and Gene Ontology (GO) analysis (Fig. 
2a-c). A heat map of the top 20 most affected transcripts showed that 5B8 inhibits fibrin-
induced transcription of a group of genes that regulate innate/adaptive immune responses 
(Fig. 2c). Reductions in the expression of Ccl24, Tnfs18, Il12b, Cxcl3, and Ifng by 5B8 
were validated by quantitative RT-PCR (Fig. 2d). 5B8 did not affect LPS-induced expression 
of proinflammatory genes (Fig. 2e), suggesting that the suppression of innate immune 
activation by 5B8 may be selective for fibrin. Further, 5B8 or its F(ab) fragment alone 
inhibited microglial activation and chemokine gene expression in fibrinogen-induced 
encephalomyelitis (Supplementary Fig. 3), an acute neuroinflammatory model resulting 
from fibrin-induced microglial activation16. Thus, we have devised a paradigm to develop a 
fibrin epitope-specific immunotherapy. The result is 5B8, a highly selective monoclonal 
antibody that blocks fibrin-induced, CD11b-mediated activation of innate immunity without 
affecting fibrin polymerization, in vivo clotting time, or aPTT in human plasma.
Fibrin induces NADPH oxidase-mediated neurodegeneration.
A consequence of activation of innate immunity in CNS autoimmune and neurodegenerative 
diseases is neurotoxicity, its successful treatment remaining a major unmet clinical need. 
Intriguingly, fibrin induced expression of several genes that regulate oxidative stress and 
ROS release (Fig. 3a) and that are implicated in neurotoxicity7,21. Ncf4, the gene that 
encodes the p40phox subunit of the NADPH oxidase Nox2 complex, was among the highest 
fibrin-upregulated genes (Fig. 3a). NADPH oxidase is a multicomponent enzyme system 
upregulated in human MS22 and AD23. Increased NADPH-oxidase activation and oxidative 
stress are common mechanisms of neurodegeneration in diseases with fibrin deposition, 
including MS, AD, stroke, traumatic brain injury, and brain aging6,24,25. Intriguingly, fibrin 
increased protein expression of the Nox2 component gp91phox, phosphorylation of p40phox, 
and NADPH oxidase activity; these increases were all reduced when macrophages were 
treated with 5B8 (Fig. 3b,c). 5B8 treatment inhibited fibrin-induced ROS release in both 
mouse and human macrophages (Fig. 3d,e). Fibrin-induced ROS generation was reduced in 
BMDMs when the p47phox subunit of NADPH oxidase was ablated genetically (p47phox–/–) 
and when NADPH-oxidase and CD11b were inhibited by treatment with apocynin or the 
anti-CD11b antibody M1/70, respectively (Fig. 3f,g and Supplementary Fig. 4a). In the 
culture conditions tested, fibrin stimulation or treatment with antibodies did not affect 
BMDM cell density (Supplementary Fig. 4b). In a co-culture of cortical neurons and 
macrophages, which recapitulates the non-cell-autonomous degeneration of CNS neurons, 
fibrin-primed macrophages induced significant loss of MAP-2+ neurons and increased 
fragmentation and blebbing of neurites (Fig. 3h). Notably, 5B8 effectively blocked this 
pathogenic cascade (Fig. 3h). These results suggest that fibrin causes neurotoxicity via a 
causal chain that involves CD11b-mediated innate immune cell activation and increased 
ROS production by NADPH oxidase.
Fibrin immunotherapy protects from axonal damage in EAE.
Evidence from human MS has underscored the contributions of fibrin, innate immunity, and 
oxidative stress to disease onset, progression, and disability3,8,9,19,22,26. To examine the role 
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of fibrin on neurotoxicity in vivo, we first tested the effects of 5B8 in three experimental 
autoimmune encephalomyelitis (EAE) models that simulate key aspects of MS: relapsing-
remitting PLP139–151 EAE, chronic MOG35–55 EAE, and adoptive transfer of CD4+ T cells 
differentiated under TH1-polarizing conditions. Given prophylactically, 5B8 reduced 
neurologic signs in all three models compared to IgG2b isotype control (Fig. 4a). Given 
prophylactically, 5B8 reduced the mean maximum clinical score and delayed the first day of 
onset as compared to the IgG2b-injected control groups (Supplementary Tables 1, 2). Given 
therapeutically, 5B8 reduced the severity of relapses in PLP139–151 EAE (Fig. 4b, 
Supplementary Table 1). In all EAE treatment groups, 5B8 reduced the percentage of 
paralyzed mice (Fig. 4c). Fibrin is a cross-linked polymer of fibrinogen molecules. 
Consequently, anti-fibrinogen antibodies detect both fibrinogen and fibrin11. Fibrinogen is 
converted to fibrin at sites of increased coagulation activity11. In EAE spinal cord, 
coagulation activity promotes the conversion of fibrinogen to fibrin, leading to parenchymal 
fibrin deposition at areas of microglia activation and demyelination27. After i.p. injection of 
biotinylated 5B8 in mice with EAE, 5B8 spatially correlated with fibrin(ogen)-rich areas in 
the spinal cord (Fig. 4d), demonstrating target engagement.
To determine whether 5B8 inhibits inflammatory cell recruitment into the CNS, we treated 
after induction of EAE in Cx3cr1GFP/+Ccr2RFP/+ mice. 5B8 inhibited both the accumulation 
of Cx3cr1+ microglia and the infiltration of Ccr2+ monocytes into the CNS (Fig. 5). 
Increased NADPH oxidase activity and excessive ROS production are implicated in MS28, 
and ROS generated by invading and resident CNS macrophages mediate demyelination and 
axonal damage in EAE7. 5B8 markedly reduced axonal damage, ROS generation, 
inflammation, and demyelination in EAE (Fig. 5, Supplementary Fig. 5a,b). In accordance 
with prior studies7,12, axonal damage correlated with ROS+ areas in EAE lesions 
(Supplementary Fig. 5c). The fibrin γ377–395 peptide inhibits binding of fibrin to CD11b and 
suppresses EAE without affecting peripheral T cell responses13. Similarly, 5B8 did not 
significantly alter peripheral T cell responses in PLP139–151 EAE mice (Supplementary Fig. 
6), suggesting that 5B8 does not modulate peripheral adaptive immune responses. These 
results suggest that systemic delivery of 5B8 in vivo is well tolerated and that fibrin 
immunotherapy suppresses innate immune activation, oxidative stress, demyelination, and 
axonal damage in EAE.
Fibrin immunotherapy protects AD mice.
Neurodegeneration driven by the innate immune system has emerged as a key pathogenic 
mechanism in AD29. We therefore tested whether blocking fibrin/CD11b interactions 
protects against amyloid-related neurodegeneration. In 5XFAD mice, in which transgenes 
encoding familial AD-mutant forms of human amyloid precursor protein and presenilin 1 
are expressed in neurons, fibrin was detected in the brain as early as 3 months of age; at 5 
months, fibrin accumulation was abundant at sites of amyloid deposition, which were 
surrounded by CD11b+ microglia (Fig. 6a, Supplementary Fig. 7a). In 5XFAD mice, fibrin 
deposits were detected in the vicinity of dystrophic neurites (Fig. 6b), a key feature of 
neurodegeneration in AD30. Systemically administered 5B8 spatially correlated with fibrin-
rich areas surrounding amyloid plaques in 5XFAD mice (Fig. 6c, Supplementary Fig. 7b), 
demonstrating brain penetration and target engagement.
Ryu et al. Page 6
Nat Immunol. Author manuscript; available in PMC 2019 April 15.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
To determine whether blocking fibrin/CD11b interactions protects against amyloid-related 
neurodegeneration, we treated 5XFAD mice with 5B8 for 2 months, starting at 3.5 months 
of age (1.5 months after appearance of amyloid plaques and microglial activation) (Fig. 7a). 
5B8 reduced reduced loss of cholinergic neurons and microglia activation around plaques in 
5XFAD mice (Fig. 7b,c) without significantly affecting amyloid plaques or the number of 
Mac2+ macrophages around plaques (Supplementary Fig. 8a,b). Whole-genome microarray 
and GO analysis of cortical gene expression in 5XFAD mice showed that 5B8 suppressed 
five key pathways: complement pathway, antigen presentation, cytokine response, lysozyme, 
and ROS (Fig. 7d). Overall, these findings suggest that blocking fibrin/CD11b signaling 
suppresses amyloid-induced neurodegeneration and reduces the expression of genes that 
promote inflammation and oxidative stress.
Fibrin immunotherapy suppresses TYROBP network genes.
Gene network analysis has broadened our understanding of AD pathogenesis by revealing 
immune gene networks as likely causal contributors to AD pathology31. Targeting these 
networks could culminate in the development of novel therapeutics. To identify gene 
networks that might be regulated by 5B8, we interrogated our transcriptomic data using 
biological network analysis. First, we performed genetic network modeling of genes 
downregulated by 5B8. We found a highly connected hub of co-expressed genes primarily 
within the complement pathway, including TYROBP (DAP12), C4b, and C1q (Fig. 8a). The 
5B8-downregulated cluster of co-expressed genes shows a striking overlap with gene 
networks implicated in the pathogenesis of human AD, including those encoding the 
TYROBP-related microglial module31. Indeed, TYROBP, encoding a co-receptor for 
CD11b and the human AD-associated receptor Trem2, was one of the top 5B8-
downregulated genes (Fig. 7d, Fig. 8a). Overlay of gene expression data obtained in 5B8-
treated 5XFAD mice with neuroinflammatory gene networks from human AD brains showed 
a reduction of human AD-related inflammatory networks by 5B8. By overlaying our data on 
a mouse version of the human AD TYROBP module31, we found that 5B8 downregulated 
65% of the Tyrobp-related network at various levels of significance, including Tyrobp at the 
nexus of the network (Fig. 8b). Several components of the TYROBP signaling pathway were 
also downregulated (Supplementary Fig. 8c). This bioinformatic approach allowed us to gain 
insights into the mechanisms of action of 5B8 treatment, as we identified downregulation of 
co-expressed genes primarily within the complement pathway that were relevant to AD 
pathogenesis. Integrated gene network analysis could be a useful tool to better understand 
the mechanism of action of new drugs and assess their efficacy in suppressing inflammatory 
gene networks relevant to human disease. Thus, fibrin inhibition by 5B8 may suppress 
pathogenic activation of innate immune pathways that mediate amyloid-related 
neurodegeneration.
Discussion
Our study revealed a previously unknown neurodegenerative pathway in which fibrin 
activates NADPH oxidase in innate immune cells to promote ROS production and 
neurotoxicity. By developing an antibody-based approach to selectively target a key 
inflammatory fibrin domain, we showed here that fibrin-targeting immunotherapy can be 
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selective and efficacious in suppressing neuroinflammation and neurodegeneration. 
Consequently, preventing fibrin from engaging this mechanism may lead to the development 
of therapeutic strategies for neurodegenerative diseases with neurovascular dysfunction. This 
discovery may have implications beyond the CNS, since fibrin deposition is a common 
thread in inflammatory pathologies, such as rheumatoid arthritis, colitis, and Duchenne 
muscular dystrophy (reviewed in11,12). Fibrin/CD11b signaling induces chemokine release 
and macrophage recruitment16 and increased NADPH oxidase activation culminating in 
ROS release and oxidative stress (this study). Therefore, inhibitors of fibrin/CD11b 
interaction, such as 5B8, have the potential to affect both inflammatory processes and 
oxidative stress. Inhibiting fibrin formation with anticoagulants can cause adverse effects by 
increasing bleeding risk32. Epitope-selective targeting of fibrin may overcome this challenge 
by selective suppression of its damaging functions without adverse anticoagulant effects. 
Overall, fibrin immunotherapy could represent a selective multi-indication therapy to 
suppress fibrin-induced chronic inflammation by inhibiting release of proinflammatory 
factors and oxidative stress at sites of increased vascular permeability in neurological and 
other inflammatory diseases.
Our study revealed a novel function of fibrin/CD11b signaling as an activator of NADPH 
oxidase-dependent ROS production. CD11b integrin-dependent respiratory bursts require 
DAP12 receptor signaling33, . CD11b and DAP12 are co-expressed in microglia and act 
synergistically to promote the production of superoxide ions and induce neuronal death33. 
Intriguingly, DAP12 was a major pathway downregulated by fibrin immunotherapy in the 
5XFAD mouse brain. Fibrin—via activation of CD11b/CD18 signaling—might increase 
DAP12 expression and potentiate CD11b/DAP12-dependent oxidative damage by promoting 
the phosphorylation and assembly of the NADPH oxidase complex34,35 and activating 
kinase pathways13. In addition to fibrin, several other immune-mediated mechanisms can 
activate NADPH oxidase, such as Aβ binding to CD36 scavenger receptor, or activation of 
CR3 or TLR4 signaling by α-synuclein or LPS25. Aβ-induced activation of NADPH oxidase 
in innate immune cells contributes to neurovascular dysfunction, neurodegeneration, and 
cognitive decline in AD mice5,36. Fibrin and Aβ may have an additive effect on NADPH 
oxidase activation via CD11b/CD18 and CD36, respectively. Genome-wide association 
studies, converged linkage analysis, and gene expression data have pointed to immune 
regulation of AD pathology. These studies, in combination with limited success of clinical 
trials targeting amyloid, have led to a reassessment of AD pathogenesis and the need for 
developing new treatments against different targets37. Vascular and amyloid pathologies are 
independent and additive predictors of cognitive decline in the elderly38,39, suggesting that 
they may need to be targeted independently for maximal therapeutic benefit. Fibrin 
immunotherapy did not reduce Aβ deposition after 2 months of administration, suggesting 
that the neuroprotective effects of inhibiting fibrin/CD11b interactions occur in the presence 
of Aβ. Future studies will determine whether fibrin/CD11b signaling and 5B8 also affect 
cognitive performance in AD mice.
Fibrin immunotherapy represents a novel approach to selectively suppress pathogenic innate 
immune responses with potential clinical implications. In MS, anti-inflammatory 
medications have little effect in the progressive phase of disease, which is mediated by 
innate immune mechanisms3,8. Other modulators of innate immunity, such as complement, 
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CR3, TNF, NF-κB, PI3K, and TLR4, are ubiquitously expressed in the brain and the 
periphery and have reported roles in regulating physiological CNS functions. In contrast, 
fibrin is not present in the normal brain, but is abundantly deposited in the CNS after BBB 
disruption11. 5B8 is selective for inhibiting innate immune activation by fibrin-CR3 
interactions and does not affect activation of macrophages by other ligands, such as LPS, 
suggesting that innate immune activation by other ligand/receptor interactions can proceed 
normally. Phagocytic pathways in innate immune cells are required for debris clearance and 
remyelination40. Fibrin-primed macrophages inhibit the differentiation of oligodendrocyte 
precursor cells41, which are susceptible to oxidative stress42. Fibrin immunotherapy could 
suppress fibrin-induced chronic inflammation and potentially promote repair by inhibiting 
oxidative stress and release of proinflammatory factors. Microglia and macrophages are 
functionally distinct populations with diverse functions in neurodegenerative diseases43–46. 
Future studies using CyToF and large transcriptomic profiling in microglia and macrophages 
will be required to determine the potential differential effects of fibrin on innate immune 
populations. The fibrin γ377–395 inflammatory epitope has been validated genetically in 
inflammatory models in the brain and periphery with findings replicated in numerous 
laboratories (reviewed in11,12). It is possible that pharmacologic targeting of fibrin-CR3 
interactions could represent a selective treatment to add to the toolbox of anti-innate immune 
therapies that may be particularly efficacious for suppressing neuroinflammation at sites of 
BBB leakage and vascular damage with fibrin deposition.
The available genetic and pharmacologic tools used to study the γ377–395 epitope (fibrinogen 
gamma chain Fgg390−396A mutant mice, γ377–395 peptide, 5B8 antibody in this study) have 
primarily revealed pathogenic functions for the γ377–395 epitope in inflammation. 
Fibrinogen alpha chain-deficient (Fga–/–) and Fgg390−396A mice13,47,48, mice treated with 
either 5B8 (this study) or γ377–395 peptide13, or anticoagulants13,26,41 are not 
immunocompromised and can be housed in conventional animal facilities without 
opportunistic infections. In humans, congenital afibrinogenemia, a genetic disorder 
characterized by complete absence of fibrinogen, is associated with excessive bleeding but 
no increase in opportunistic infections49. Fibrin inhibits repair as persistent fibrin deposition 
inhibits wound healing50, while fibrinogen depletion increases remyelination41,51. These 
studies do not exclude the possibility that the fibrinogen γ377–395 epitope may have 
physiological functions that have not yet become apparent using the genetic and 
pharmacologic tools available. Collectively, prior genetic studies on the γ377–395 epitope and 
our findings support that fibrin is inducing, in a ligand-selective manner, a specific gene 
signature in immune cells that produces primarily pathogenic functions. Consequently, 
targeting fibrin-induced activation of innate immunity has the potential to suppress 
proinflammatory and neurotoxic pathways without significant interference with protective 
functions of the innate immune system. Future immunotoxicology studies will also be 
required to fully test potential immune dysfunction in the context of fibrin immunotherapy.
Fibrinogen is a coagulation factor essential for blood clotting. Studies in Fgg390−396A mice 
have shown that the γ377–395 epitope is not required for fibrin polymerization, platelet 
aggregation, and does not increase bleeding risk48. Fgg390−396A mice have normal 
fibrinogen concentrations, fibrin polymerization, platelet aggregation, normal thrombus 
formation in FeCl3-injured carotid arteries, pregnancy and birth rates. Furthermore, they do 
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not develop spontaneous hemorrhagic events and tolerate major surgical procedures (e.g., 
abdominal surgeries), without inordinate bleeding48. In contrast to Fgg390−396A mice, Fga–/– 
mice that lack fibrinogen exhibit broad hemostatic abnormalities secondary to the lack of 
clotting function and failure of fibrinogen-supported platelet aggregation, and uniformly 
cannot sustain pregnancies due to hemostatic requirements at the placenta-maternal 
interface47, a phenotype also observed in mice lacking fXIIIA52. Consistent with 
experimental findings in Fgg390−396A mice, the fibrin γ377–395 peptide does not inhibit 
normal clotting time in vivo or fibrin polymerization in vitro13. Our study shows that 5B8 
does not affect normal clotting time in vivo, fibrin polymerization in vitro, or aPTT in 
human plasma. Similar to the Fgg390−396A mice, mice treated with 5B8 even for prolonged 
periods up to ~2 months did not develop any spontaneous bleeding. The 5B8 γ377–395 
epitope does not overlap with the γ398–406 residues known to be enzymatically cross-linked 
by transglutaminase fXIII53. Nevertheless, comparative studies of fXIII-mediated 
crosslinking in vitro and in vivo will be of interest in future studies of 5B8. This is could be 
of particular interest in light of studies of Fgg390−396A mice in a model of venous 
thrombosis54. Here, Fgg390−396A mice were shown to maintain fXIII-mediated γ chain 
cross-linking but at a reduced rate, and this resulted in smaller venous thrombi. Overall, 
studies in Fgg390−396A mice48, data obtained with the fibrin γ377–395 peptide13 and in this 
study suggest that the γ377–395 epitope and 5B8 do not interfere with fibrin clotting and 
presents limited risk of spontaneous hemorrhagic events. Future toxicology studies will be 
required to determine whether 5B8 may interfere with other features of hemostasis and 
thrombosis.
Together, data from human pathology, genetic and pharmacologic studies in mice, 
transcriptomic and signal transduction studies establish fibrin as a dual inflammatory and 
oxidative stress signal in the CNS and suggest that fibrin immunotherapy could prevent 
neurodegeneration and other complications in conditions associated with fibrin deposits at 
sites of BBB disruption. Fibrin immunotherapy may hold promise as a new therapeutic 
strategy for neurological and inflammatory disorders with vascular damage.
Methods
Methods, including statements of data availability and any associated accession codes and 
references, are available at <insert link here>
Animals.
SJL/J, C57BL/6, Cx3cr1GFP/+ 55, Thy1-YFP (Tg(Thy1-YFP)HJrs)56, 5XFAD (B6SJL-Tg 
(APPSwFlLon,PSEN1*M146L*L286V) 6799 Vas/Mmjax)57, and p47phox–/–58 mice were 
purchased from The Jackson Laboratory and Sprague-Dawley rat P0 litters from Charles 
River Laboratories. 5XFAD were crossed with Thy1-YFP to generate 5XFAD:Thy1-YFP 
mice. Ccr2RFP/RFP on a C57BL/6 background provided by I. F. Charo (Gladstone Institutes), 
and bred to generate Cx3cr1GFP/+Ccr2RFP/+ mice59. Mice were housed in groups of five 
under standard vivarium conditions and a 12 h light/dark cycle. All animal protocols were 
approved by the Committee of Animal Research at the University of California, San 
Francisco, and in accord with the National Institutes of Health guidelines.
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Mouse mAb production.
Synthesis of human fibrinogen γ190–202 and γ377–395 peptides and mouse monoclonal 
antibody production was performed by A&G Pharmaceuticals. Screening of 480 hybridomas 
was performed by ELISA against peptides or the carrier protein. Positive clones were 
expanded and retested to confirm peptide epitope reactivity to either γ190–202 or γ377–395. 
Target candidates were identified as outlined in Supplementary Fig. 1a. The structural map 
of the γC-domain of fibrinogen was generated using the PyMOL Molecular Graphics 
System, Version 1.6 Schrödinger, LLC with PDB ID 1FIC .
Peptide Binding assays.
Human γ377–395 peptide (Genscript) in carbonate buffer (0.1 M NaHCO3 and 0.15 M NaCl) 
was coated onto MaxiSorp ELISA plates (Thermo Fisher Scientific) overnight at 4 °C. Wells 
were incubated with blocking buffer (3% bovine serum albumin (BSA) and 0.1% NP-40 in 
PBS) for 2 h at 25 ˚C, washed with PBS 0.05% Tween-20. Antibodies 5B8, 4F1, 4E11, 1E3 
were diluted in blocking buffer and added to the wells for 2 h at 25 ˚C followed by 
secondary polyclonal goat anti-mouse IgG/HRP (#P0447, DAKO) in blocking buffer for 2 h 
at 25 ˚C and developed by TMB substrate (Sigma-Aldrich) with 450nm absorbance measured 
with an Envision Microplate reader (Perkin Elmer). For competition ELISA, the 5B8 
antibody was diluted to 2 nM in blocking buffer and preincubated with increasing 
concentrations of human or mouse γ377–395 and γ190–202 peptides for 3 h at 25 ˚C. 
Competition of 5B8 to γ377–395 or γ190–202 was assessed by incubating on plates coated 
with human γ377–395 peptide.
Fibrin/Fibrinogen binding.
Human plasminogen-free fibrinogen (#341578, EMD Millipore) was IgG depleted using 
Pierce albumin/IgG removal kit (Thermo Fisher Scientific). 25 μg/ml IgG-depleted human 
plasminogen-free fibrinogen in 20 mM HEPES pH 7.4 buffer was treated with 0.3 U/ml 
bovine thrombin (Sigma-Aldrich) and 7 mM CaCl2 in MaxiSorp ELISA plates (Thermo 
Fisher Scientific) for 1.5 h at 37 °C. Formed fibrin was dried onto the wells at 37 °C 
overnight. 25 μg/ml IgG-depleted human fibrinogen was coated onto the wells at 37 °C for 
2.5 h. Plates were washed with binding buffer (10 mM HEPES, pH 7.4 150 mM NaCl, 3 
mM EDTA, and 0.05% Tween-20) and incubated with blocking buffer (binding buffer 
containing 3% BSA) for 1 h at 25 ˚C. Monoclonal antibodies in blocking buffer were 
incubated for 1 h at 25 ˚C. Following washing with binding buffer, polyclonal goat anti-
mouse IgG/HRP (#P0447, DAKO) in blocking buffer was added for 1 h at 25 ˚C and signal 
was developed by Lumi-Phos HRP (Lumigen) measured with an Envision Microplate reader. 
Experiments of antibody binding to peptides, fibrin, and fibrinogen performed at the 
Gladstone Institutes were independently reproduced at the UCSF Small Molecule Discovery 
Center and at Lundbeck, US with similar results.
CD11b I-domain production.
pET15-His-TEV-CD11b was constructed by cloning the CD11b I-domain (residues Q130-
S326) into a pET15b-derived plasmid at the NdeI and XhoI sites, preceded by an N-terminal 
6xHis tag and followed by a TEV protease cleavage site (pET15-His-TEV-CD11b), then 
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transformed into Rosetta2(DE3) cells. Protein was expressed and purified as described60, 
with the exception that cells were lysed using a pressure driven microfluidizer and His-
containing proteins were trapped using TALON cobalt affinity resin. Protein purity was 
assessed to be > 90% by LC/MS and gel electrophoresis.
CD11b I-domain ELISA.
96-well ELISA plates (Greiner) were coated with 25 μg/ml fibrin or fibrinogen and 
incubated in blocking buffer as indicated for binding assays for 1 h prior to addition of 50 μl 
per well of biotinylated CD11b I-domain in PBS with 0.5% BSA and 0.05% Tween-20 for 2 
h at 37 °C, followed by incubation with 1 μg/ml HRP-coupled Streptavidin (BD 
Pharmingen, 1:1000) for 1 h at 25 ˚C and developed by incubation with TMB/E substrate 
(Chemicon-Millipore) and absorbance measured at 450nm with a Synergy H4 plate reader 
(BioTek). For 5B8 competition ELISA, after incubation in blocking buffer, 5B8 antibody 
was diluted at 2-fold concentrations from 0.02 μM to 10 μM and incubated for 2 h at 37 °C, 
followed by an incubation of 6.88 μM CD11b I-domain for 2 h at 25 ˚C.
Cell Culture.
Primary microglia and BMDMs were isolated, cultured, and treated with fibrin or LPS as 
previously described16. PBMCs (AllCells) (2×106 cells/mL) were plated in RPMI-1640 
media supplemented with 10% heat-inactivated FBS, 1% penicillin-streptomycin, and 50 
ng/ml human M-CSF (#300–25, Peprotech) in tissue-culture treated dishes (Corning). After 
24 h, non-adherent cells were removed, and adherent cells were cultivated for 7–8 additional 
days at 37 °C in 5% CO2.
Morphometry.
Primary microglia were stimulated with fibrin for 48 has described16. Microglia were fixed 
with 4% PFA, permeabilized with 0.1% Triton X-100 and immunostained with FITC-labeled 
Isolectin B4 (1:300; Sigma-Aldrich) and/or CellMask™ Red Stain (Thermo Scientific). 
Blocking involved pre-incubation with 80 μg/ml antibodies or mouse IgG2b (clone MPC-11, 
BioXCell BE0086 distributed by the UCSF Monoclonal Antibody Core, endotoxin 
concentrations < 0.002 EU/μg) or IgG2b (eBiosciences endotoxin level < 0.01 EU/μg) for 2 
h at 37 °C before plating of cells for a final concentration of antibodies at 40 μg/ml. Manual 
Analysis: Images were collected using an Axioplan 2 Zeiss microscope with an Axiocam 
HRc camera and analyzed using ImageJ. 250 cells per condition were counted for each 
experiment. Activated microglia were classified based on a surface area > 2,000 μm2. 
Automated Image Acquisition and Analysis: Images of microglia cells were acquired with 
the GEHC IN-Cell Analyzer 2000™, using a 10× lens and excitation/emission filter pairs of 
350nm/455nm (CellMask™ Red Stain) and 579nm/624nm (Hoechst dye). Images were 
analyzed with the GEHC IN-Cell Developer Toolbox version 1.9. The Hoechst-stained 
nuclei were segmented using a “nuclear” segmentation type, with a set minimum target area 
of 30 μm2 and set sensitivity of 75%. To minimize artifacts, segmentation with less than 120 
intensity units or area greater than 1000 μm2 were excluded. The CellMask™ Red-stained 
whole microglia cells were segmented using an “intensity” segmentation type, with a set 
threshold between 200 – 4095 intensity units. The borders of adjacent contacting cells were 
resolved using the “clump breaking” segmentation post-processing, which utilizes discrete 
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nuclei as seeds. For segmented by size cells > 800 μm2 were classified as activated 
microglia. Only cells containing a nucleus within the cell body area were accepted. All 
segmented nuclei and cells were then recorded as individual counts.
Fibrin polymerization assay.
Human fibrinogen was diluted to 0.15 mg/ml in 20 mM HEPES (pH 7.4) containing 0.15 M 
NaCl and 5 mM ε-amino caproic acid and combined with 0.3 U/ml thrombin (Sigma-
Aldrich), and 10 mM CaCl2. Antibodies (50 μg/ml) or GPRP peptide (Bachem) were 
incubated with fibrinogen for 2 h at 37 °C before mixing with CaCl2/thrombin. Absorbance 
at 350nm over intervals of 60 s was measured using a SpectraMax M5 microplate reader 
(Molecular Devices) with SoftMax Pro 5.2 software (Phoenix Technologies Ltd.).
Plasma clotting time and aPTT assay.
Plasma-clotting times were measured as described13 by combining equal volumes of citrated 
plasma and 2 U/ml bovine thrombin (Enzyme Research Laboratories) and 40 mM CaCl2 at 
37 °C. aPTT assay was performed in pooled normal human plasma (Innovative Research) 
using 50 μg/ml 5B8 or IgG2b or 0.5 mM GPRP peptide (Bachem). Plasma was incubated 
with 5B8 or IgG2b at 37 °C for 2 h. Clotting was initiated by aPTT-XL (Ellagic acid 
activator) and 0.02 M CaCl2 (Thermo Fisher Scientific) and monitored at 405nm in a 
SpectraMax M5 microplate reader.
Real time qPCR, multi-plex qPCR and microarray analysis.
RNA isolation, real-time PCR, and microarray analysis were performed as described16. 
Primers are listed in Supplementary Table 3. Microarray data from GEO GSE71084 were 
used to select ROS genes with significant log2 expression to generate heat maps for primary 
microglia and BMDMs. For multiplex qPCR, primary microglia were plated in 96-well 
black μ-clear-bottom microtiter plates (Greiner Bio-One) in DMEM, 10 % FBS, 1 % 
penicillin/streptomycin and allowed to adhere for 24 h prior to being treated for 4 h with 1 
μM fibrin D-dimer (HyTest) as described12. 20 μg/ml 5B8 or IgG2b were pre-incubated with 
fibrin D-dimer in DMEM for 3 h at 37 ºC before cell treatment. Gene expression was 
assessed using the RT2 Profiler PCR Array (Rat Inflammatory & Autoimmunity; Qiagen), 
and only differentially expressed genes (fold > 2, P < 0.05) were reported as the mean fold 
change. Gene expression antibody inhibition experiments performed at the Gladstone 
Institutes were independently reproduced at Lundbeck, US with similar results.
Oxidant detection with DHE.
BMDMs or PBMCs were incubated in RPMI containing 5 μM DHE (Invitrogen) for 30 min. 
100,000 cells/well were plated on 96-well black μ-clear-bottom microtiter plates (Greiner 
Bio-One) precoated with 25 μg/ml fibrin. 20 μg/ml 5B8 or IgG2b (UCSF Monoclonal 
Antibody Core clone LTF-2) were added in fibrin-coated wells 2 h before plating cells. 
BMDMs were incubated with 300 μM apocynin (Calbiochem) for 1 h or 5 μg of anti-CD11b 
(M1/70, eBioscience) for 30 min before plating. Cells were incubated on fibrin for 24–48 h, 
fixed with 4% PFA for 10 min, and DHE fluorescence was detected at 518nm/605nm using 
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SpectraMax M5 microplate reader. Cells were quantified by DAPI counterstaining. In mice, 
in vivo DHE administration and detection was performed as described15.
NADPH oxidase activity.
BMDMs were plated on 25 μg/ml fibrin-coated 6-well plates (Greiner Bio-One). 20 μg/ml 
5B8 or IgG2b were added to the fibrin plates 2 h before plating cells. NADPH oxidase 
activity was assayed by the lucigenin-enhanced chemiluminescence method61. Cells were 
collected by a cell scraper and homogenized in ice-cold Krebs buffer pH 7.4 (119 mM NaCl, 
2.5 mM KCl, 1mM NaH2PO4, 1.3 mM MgCl2, 2.5 mM CaCl2, 11 mM glucose, and 20 mM 
HEPES, pH 7.4). The cell homogenate was centrifuged at 1000g, and the pellet was 
resuspended with luminescence buffer (Krebs buffer containing 10 μM lucigenin, Cayman 
Chemicals), before adding 100 μM NADPH substrate (Sigma-Aldrich). Luminescence was 
detected by an EnSpire microplate reader.
Immunoblots.
BMDMs cultured on 25 μg/ml fibrin-coated plates were lysed in RIPA lysis buffer (EMD 
Millipore) with protease/phosphatase inhibitor cocktail (EMD Millipore). Protein extracts 
(20 μg) were separated by electrophoresis on NuPAGE 4–12% Bis-Tris Gel (Life 
Technologies) and transferred onto nitrocellulose. Blots were blocked in 5% milk in TBST 
and incubated with gp91phox (1:1000; clone EPR6991, Abcam), Phospho-p40phox (1:1000; 
Thr154, Cell Signaling Technology), and GAPDH (1:5000; clone 14C10, Cell Signaling 
Technology) using horseradish peroxidase-conjugated secondary antibody (1:5000; Cell 
Signaling Technology #7074S) and enhanced chemiluminescence (ECL) kit (GE 
Healthcare) for detection. Densitometry analysis was performed using ImageJ.
Cortical neuron-macrophage co-culture.
Cortices from P1 rats were finely minced and digested for 30 min at 37 °C in DPBS (Gibco) 
containing papain (Worthington Biochemicals) and DNase (Sigma-Aldrich). Papain was 
inhibited by the addition of ovomucoid (Worthington Biochemicals). Neurons were plated at 
a density of 60,000 cells/cm2 on poly-D-lysine pre-coated 8-well Permanox chamber slides 
(Sigma-Aldrich) in Neurobasal/B27 medium (Invitrogen) and cultured for 10 days. Rat 
BMDMs were cultured in RPMI-1640 with 10% heat-inactivated FBS (Invitrogen), 1% 
penicillin-streptomycin (Corning), and 10 ng/ml rat M-CSF (#400–28, Peprotec). BMDMs 
were plated on 25 μg/ml fibrin-coated plates with 20 μg/ml 5B8 or IgG2b for 24 h and were 
lifted with PBS-EDTA as described16 and added to cortical neuron cultures for two days, 
fixed with 4% PFA and immunostained with anti-MAP-2 (1:1000; clone AP20, EMD 
Millipore) and thresholded images were quantified with the NeurphologyJ plug-in in 
ImageJ. 2.5 × 1010 GC/ml of AAV1.hSyn.TurboRFP (University of Pennsylvania Vector 
Core) was used to transduce primary cortical neurons for 8 d prior to the addition of fibrin-
stimulated BMDMs for 12 h. RFP images were thresholded and the neurite fragments were 
analyzed using the ImageJ plugin ‘Analyze Particles’. Quantification was performed by an 
observer blinded to the experimental treatments.
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Pharmacokinetics.
C57BL/6 mice were injected with 400 μg 5B8 i.p. Blood samples were collected by micro-
accusampler and centrifuged at 2500 rpm for 15 min. Plasma was stored at −80 °C until 
analysis. Plasma was diluted 1:1000 in blocking buffer (3% BSA and 0.1% NP-40 in PBS). 
5B8 was diluted in blocking buffer to create a concentration curve. Plasma and 5B8 were 
added to wells coated with human γ377–395 peptide and incubated for 2 h at 25 ˚C. After 
washing, polyclonal goat anti-mouse IgG-HRP (#P0447, DAKO) in blocking buffer was 
added for 2 h at 25 ˚C and the assay was developed with TMB Liquid substrate (Sigma-
Aldrich) with absorbance measured using an Envision Microplate reader.
EAE.
EAE was induced in 8–9-week-old female SJL/J, C57BL/6, or Cx3cr1GFP/+Ccr2RFP/+ mice 
by subcutaneous immunization with 100 μg PLP139–151 (HSLGKWLGHPDKF; Auspep Pty 
Ltd) or 50 μg MOG35–55 (MEVGWYRSPFSRVVHLYRDGK; Auspep Pty Ltd) in complete 
Freund’s adjuvant (Sigma-Aldrich) supplemented with 400 μg of heat-inactivated 
mycobacterium tuberculosis H37Ra (Difco Laboratories). Two days after immunization, 
mice were injected i.p. with 200 ng (C57BL/6) or 75 ng (SJL/J) pertussis toxin (Sigma-
Aldrich). For adoptive transfer, donor SJL/J mice were immunized as described above, and 
on day 10, cells from draining lymph nodes and spleen were isolated. Lymphocytes were re-
stimulated with 20 μg/ml PLP139–151 peptide and 10 ng/ml of IL-12 (eBioscience) for 4 d, 
and 3 × 107 cells were transferred into healthy SJL/J recipients. Frequency of donor CD4+ T 
cells producing IFNγ by FACS was assessed before transfer. For prophylactic treatment, 
mice were each given 800 μg of either 5B8 or isotype-control IgG2b every two days from 
day 0. For therapeutic treatment, antibodies were injected every two days starting at the peak 
of the initial paralytic episode. Mice were observed daily and clinical scores were assessed 
by observers blinded to treatments as follows: 0, no symptoms; 1, loss of tail tone; 2, ataxia; 
3, hindlimb paralysis; 4, hindlimb and forelimb paralysis; 5, moribund.
Histology and immunohistochemistry.
For histological analysis, spinal cords and brains were processed as described13,62. 
Antibodies used were: mouse anti-neurofilament H non-phosphorylated (1:100; BioLegend 
clone SMI-32), rabbit anti-Iba-1 (1:1000; Wako #019–19741), and mouse anti-myelin basic 
protein (1:100; BioLegend clone SMI-99) and Alexa Fluor 488 or 594 (1:500; Jackson 
ImmunoResearch) for detection. Immunohistochemistry for anti-MBP was performed with 
the Mouse on Mouse (M.O.M.) kit (Vector Labs). Ccr2RFP/+Cx3cr1GFP/+ mice were 
perfused with 4% PFA and spinal cord segments were frozen in OCT, then cut into 10-μm 
sections and stained with DAPI for 5 min. DHE labeling was performed as described 15. For 
analysis of 5XFAD mice, mice were perfused with 4% PFA and brains were postfixed in 4% 
PFA overnight at 4 °C, except for CD11b staining, which was postfixed for 4 h. 
Immunohistochemistry in coronal brain sections (30 μm) were performed using antibodies 
against ChAT (1:1000, EMD Millipore #AB144P), CD11b (1:150; eBioscience clone 
M1/70), Iba-1 (1:1000; Wako), Mac-2 (1:1000; Cedarlane clone M3/38), fibrinogen (1:1000; 
J. L. Degen, Cincinnati Children’s Hospital Medical Center), and human Aβ (1:500; IBL-
America #18584). Amyloid plaques were labeled with methoxy-XO4 (fluorescent probe for 
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Aβ, Tocris) as described63. Images were acquired with an Axioplan II epifluorescence 
microscope (Zeiss) equipped with dry Plan-Neofluar objectives (10 × 0.3 NA, 20 × 0.5 NA, 
or 40 × 0.75 NA) or all-in-one BZ-X700 fluorescence microscope (Keyence) or a Fluoview 
FV1000 (Olympus) confocal microscope and FluoView Software v3.1b. Excitation lasers 
were set to 405, 488, and 543nm and Olympus 20 × 1.00 NA, Olympus 25 × 1.05 NA, or an 
Olympus 40 × 0.8 NA water immersion lens with 1.0 μm z-step and Kalman filtering using 
line mode of 2 were used. Iba1, Aβ, Mac2+ quantification was averaged from 9 field of 
views of high Aβ plaque density throughout the cortex. Images were quantified using 
ImageJ by observers blinded to the experimental conditions.
Flow cytometry.
Primary mouse splenocytes were isolated from 5B8- and IgG2b-treated mice 10 days after 
immunization with PLP139–151. Cell suspensions were stained with combinations of 
antibodies: CD45 (BioLegend clone 30-F11), CD3 (BioLegend clone 17A2), CD4 
(BioLegend clone GK1.5), CD11b (BioLegend clone M1/70), B220 (BD Bioscience clone 
RA3–6B2), Ly6G (eBioscience clone RB6–8C5), and CD11c (BioLegend clone N418). For 
cytokine analysis, cells were incubated for 4 h with Cell Activation Cocktail (BioLegend) 
and surface stained for CD3, CD4, and CD8 (BioLegend clone 53–6.7). Cells were then 
fixed with Cytofix/Cytoperm solution (BD Biosciences), and intracellular cytokine staining 
was performed with anti-IFN-γ (BioLegend clone XMG1.2) and anti-IL-17-FITC 
(BioLegend clone TC11–18H10.1). All antibodies were used at 1:300. Flow cytometry was 
performed on an LSR II (BD Biosciences). Data were analyzed using FlowJo (Tree Star).
Stereotactic fibrinogen injection and drug treatment.
Stereotactic injection of fibrinogen into the corpus callosum of Cx3cr1GFP/+ or C57BL/6 
mice and analysis were performed as described15,16. 5B8, or 5B8-F(ab) fragment, or 
isotype-control IgG2b (clone MPC-11, eBioscience) was injected (10 μg at 0.2 μl/min) into 
the cerebral ventricle (AP, −2.0 mm; ML, 0 mm, DV, −2.0 mm) with a 10-μl syringe 
attached to a 33-gauge needle 30 min before fibrinogen injection.
5B8 penetration in the CNS and target engagement.
Mice were injected i.p. with 800 μg/mouse of biotinylated 5B8 every 2 days (3 total doses). 
Mice were perfused with saline, and spinal cord or brain were processed for fresh frozen 
sections as described. Sections were fixed with 4% PFA for 10 min and biotinylated 5B8 
was detected using Cy3-conjugated streptavidin (1:100; Invitrogen) for 30 min at 25 ˚C. 
Sections were incubated for 1h with fibrinogen antibody (1:2000), followed by FITC donkey 
anti-rabbit (1:500; Jackson ImmunoResearch) for 30 min at 25 ˚C. For amyloid plaque 
staining, sections were counterstained with Methoxy-X04 (Tocris; 4% vol of 10 mg/ml).
Two-photon in vivo imaging.
Thy1-YFP and Thy1-YFP:5XFAD mice were injected with Alexa594-conjugated fibrinogen 
(Invitrogen) intravenously daily for 3 days as described15. Mice were also injected i.p. with 
Methoxy-X04 24 h prior to imaging. Methoxy-X04 was solubilized with DMSO:propylene 
glycol:PBS pH 7.5 (ratio 2:9:9) at 5 mg/ml. On day of imaging, a small craniotomy was 
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made and a custom-made metal plate affixed to a stage to stabilize the skull. Alexa594-
fibrinogen solution was injected retro-orbitally prior to imaging. The anesthetized animal 
was placed on a heated pad under an Ultima-IV multiphoton microscope (Prairie) equipped 
with MaiTai DeepSee-eHP lasers (Spectra Physics). The excitation wavelength was 820nm to 
simultaneously visualize fibrinogen, methoxy-X04 and YFP dendrites. Imaging was 
performed from 20 to 150 μm below the dura, using a Nikon 40 × 0.8 NA -immersion lenses 
with a 1.0 μm z-step. z-stacks of images were projected along the z-axis to recreate two-
dimensional representations of the 3D structures within the imaged volumes. Images were 
adjusted for brightness, contrast and background noise with ImageJ. Spectral unmixing 
plugin in ImageJ was used to separate overlapping signals.
Network analyses.
The TYROBP network and the Microglia Pathogen Phagocytosis Pathway were translated 
from human-specific, static figures to mouse-specific data models using WikiPathways73 
and HomoloGene, The coexpression network was constructed by extracting the dominant 
cluster of downregulated genes of interest (selected from those with log2 fold change of 
−0.02 or less and raw P-value < −0.05) based on coexpression interaction data provided by 
GeneMANIA74. Subsequent network visualization, layout, data overlays and subnetwork 
extraction were performed in Cytoscape75.
Statistical analyses.
Data are presented as mean ± s.e.m. Statistical calculations were performed with GraphPad 
Prism (Version 6.03). Sample sizes were based on previous experiments and not 
predetermined by statistical methods. Statistical significance was determined with non-
parametric two-sided Mann-Whitney test, Kruskal-Wallis test, Welch’s two-sample t-test, 
one-way or two-way analysis of variance followed by Bonferroni or Tukey’s post-test 
(multiple comparisons). Linear models were fitted for each gene using the Bioconductor 
‘limma’ package in R64. Moderated t-statistics, fold change and the associated P values were 
calculated for each gene. Mice were randomly assigned to experimental groups for EAE and 
5XFAD experiments. Scoring of EAE mice was performed in a blinded fashion. All animals 
survived until the end of the study and all data points were included in analysis. All 
histopathological analysis and quantification was performed blinded.
To compare EAE clinical scores, the linear mixed effects models were performed using the 
R statistical package. Means of maximum clinical scores were compared using a two-sample 
t-test as implemented in R using the Welch’s t-test and the Wilcoxon rank sum test. P-values 
were corrected for multiple testing using the Holm procedure. The statistical significance of 
the changes in the mean clinical score for each day of the experiment was estimated using 
permutation tests. The corresponding p-values were estimated using 1000 permutations in all 
prophylactic antibody treatment and 10000 permutations for therapeutic antibody treatment. 
In each permutation, mice were randomly permuted. To compare the first day of onset, the 
log-rank test was used as implemented by the survdiff function in the survival package in R.
Ryu et al. Page 17
Nat Immunol. Author manuscript; available in PMC 2019 April 15.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgements
We thank J.L. Degen for expert advice and critical reading of the manuscript and S. Pintchovski, I. Kadiu, J. Palop, 
and J. Egebjerg for insightful discussions. We thank B. Cabriga, R. Meza Acevedo, L. Ta, and A. Williams for 
expert technical assistance, G. Maki for graphics, G. Howard and K. Claiborne for editorial. The Gladstone Center 
for In Vivo Imaging Research was supported in part by grants from H. Lundbeck A/S, the S.D. Bechtel, Jr. 
Foundation, and the Conrad N. Hilton Foundation 17348 to K.A. The microscopy studies were carried out in part at 
facilities adapted for this project at the National Center for Microscopy and Imaging Research, which is supported 
by grant P41 GM10341 awarded to M.H.E. Gladstone Institutes was supported by NIH/NCRR grant RR18928. The 
Mouse Pathology Core of the UCSF Helen Diller Family Comprehensive Cancer Center was supported by 
CA082103. J.K.R, D.D., and A.S.M. were supported by National Multiple Sclerosis Society (NMSS) Postdoctoral 
Fellowships; J.K.R. and D.D by Race to Erase MS Young Investigator Awards and American Heart Association 
(AHA) Scientist Development Grants; V.A.R. by postdoctoral fellowships from AHA and NIH/NINDS F32 
NS096920; A.S.M. by NIAID T32AI733429 and NMSS FG-1708–28925, K.K.H. by NSF predoctoral fellowship 
DGE-0648991/1144247; M.A.P. by a NIH/NICHD K12-HD072222; L.M. by a gift from the Dolby Family; S.S.Z. 
by NIH R01 NS092835; R21 NS108159, NMSS RG1701–26628, RG 5179A10/2, the Weill Institute, and the 
Maisin Foundation; R.A.S by NIH R01 NS081149. This work was supported by grants from NMSS RG3782, H. 
Lundbeck A/S, the Conrad N. Hilton Foundation 17348, a gift from the Levine Family, and NIH/NINDS R01 
NS052189, R21 NS082976, and R35 NS097976 to K.A.
H. Lundbeck A/S sponsored research in K.A.’s laboratory at the Gladstone Institutes. K.A. is a co-founder and 
scientific advisor of MedaRed, Inc. K.A. is an inventor on University of California issued patents US7807645, 
US8569242, US8877195, and US8980836 covering fibrin antibodies. K.A. and J.K.R are co-inventors on Gladstone 
Institutes issued patent US9669112 covering fibrin in vivo models and Gladstone Institutes pending 
US20160320370 patent application covering in vitro fibrin assays. K.A., A.M.F., M.R.A., and K.K.A. are co-
inventors on the Gladstone Institutes and University of California pending US20170003280 patent application 
covering assays for inhibition of microglia activation. Their interests are managed by the Gladstone Institutes in 
accordance with its conflict of interest policy. J.B.S., R.B.N., S.B.P, L.O.P, V.M., S.H.Z. were Lundbeck employees 
during the time the work was performed.
References
1. Rivest S Regulation of innate immune responses in the brain. Nat Rev Immunol 9, 429–439 (2009). 
[PubMed: 19461673] 
2. Ransohoff RM & Brown MA Innate immunity in the central nervous system. J Clin Invest 122, 
1164–1171 (2012). [PubMed: 22466658] 
3. Lassmann H, van Horssen J & Mahad D Progressive multiple sclerosis: pathology and pathogenesis. 
Nat Rev Neurol 8, 647–656 (2012). [PubMed: 23007702] 
4. Schuh C et al. Oxidative tissue injury in multiple sclerosis is only partly reflected in experimental 
disease models. Acta Neuropathol 128, 247–266 (2014). [PubMed: 24622774] 
5. Heppner FL, Ransohoff RM & Becher B Immune attack: the role of inflammation in Alzheimer 
disease. Nat Rev Neurosci 16, 358–372 (2015). [PubMed: 25991443] 
6. Lassmann H Mechanisms of neurodegeneration shared between multiple sclerosis and Alzheimer’s 
disease. J Neural Transm 118, 747–752 (2011). [PubMed: 21373761] 
7. Nikic I et al. A reversible form of axon damage in experimental autoimmune encephalomyelitis and 
multiple sclerosis. Nat Med 17, 495–499 (2011). [PubMed: 21441916] 
8. Chitnis T & Weiner HL CNS inflammation and neurodegeneration. J Clin Invest 127, 3577–3587 
(2017). [PubMed: 28872464] 
9. Frischer JM et al. The relation between inflammation and neurodegeneration in multiple sclerosis 
brains. Brain 132, 1175–1189 (2009). [PubMed: 19339255] 
10. Zhao Z, Nelson AR, Betsholtz C & Zlokovic BV Establishment and Dysfunction of the Blood-
Brain Barrier. Cell 163, 1064–1078 (2015). [PubMed: 26590417] 
11. Petersen MA, Ryu JK & Akassoglou K Fibrinogen in neurological diseases: mechanisms, imaging 
and therapeutics. Nat Rev Neurosci 19, 283–301 (2018). [PubMed: 29618808] 
Ryu et al. Page 18
Nat Immunol. Author manuscript; available in PMC 2019 April 15.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
12. Davalos D & Akassoglou K Fibrinogen as a key regulator of inflammation in disease. Semin 
Immunopathol 34, 43–62 (2012). [PubMed: 22037947] 
13. Adams RA et al. The fibrin-derived gamma377–395 peptide inhibits microglia activation and 
suppresses relapsing paralysis in central nervous system autoimmune disease. J Exp Med 204, 
571–582 (2007). [PubMed: 17339406] 
14. Ugarova TP et al. Sequence gamma 377–395(P2), but not gamma 190–202(P1), is the binding site 
for the alpha MI-domain of integrin alpha M beta 2 in the gamma C-domain of fibrinogen. 
Biochemistry 42, 9365–9373 (2003). [PubMed: 12899623] 
15. Davalos D et al. Fibrinogen-induced perivascular microglial clustering is required for the 
development of axonal damage in neuroinflammation. Nat Commun 3, 1227 (2012). [PubMed: 
23187627] 
16. Ryu JK et al. Blood coagulation protein fibrinogen promotes autoimmunity and demyelination via 
chemokine release and antigen presentation. Nat Commun 6, 8164 (2015). [PubMed: 26353940] 
17. Yates RL et al. Fibrin(ogen) and neurodegeneration in the progressive multiple sclerosis cortex. 
Ann Neurol 82, 259–270 (2017). [PubMed: 28719020] 
18. Marik C, Felts PA, Bauer J, Lassmann H & Smith KJ Lesion genesis in a subset of patients with 
multiple sclerosis: a role for innate immunity? Brain 130, 2800–2815 (2007). [PubMed: 
17956913] 
19. Lee NJ et al. Spatiotemporal distribution of fibrinogen in marmoset and human inflammatory 
demyelination. Brain 141, 1637–1649 (2018). [PubMed: 29688408] 
20. Strickland S Blood will out: vascular contributions to Alzheimer’s disease. J Clin Invest 128, 556–
563 (2018). [PubMed: 29388925] 
21. Nathan C & Cunningham-Bussel A Beyond oxidative stress: an immunologist’s guide to reactive 
oxygen species. Nat Rev Immunol 13, 349–361 (2013). [PubMed: 23618831] 
22. Fischer MT et al. NADPH oxidase expression in active multiple sclerosis lesions in relation to 
oxidative tissue damage and mitochondrial injury. Brain 135, 886–899 (2012). [PubMed: 
22366799] 
23. Shimohama S et al. Activation of NADPH oxidase in Alzheimer’s disease brains. Biochem 
Biophys Res Commun 273, 5–9 (2000). [PubMed: 10873554] 
24. Ma MW et al. NADPH oxidase in brain injury and neurodegenerative disorders. Mol Neurodegener 
12, 7 (2017). [PubMed: 28095923] 
25. Haslund-Vinding J, McBean G, Jaquet V & Vilhardt F NADPH oxidases in oxidant production by 
microglia: activating receptors, pharmacology and association with disease. Br J Pharmacol 174, 
1733–1749 (2017). [PubMed: 26750203] 
26. Han MH et al. Proteomic analysis of active multiple sclerosis lesions reveals therapeutic targets. 
Nature 451, 1076–1081 (2008). [PubMed: 18278032] 
27. Davalos D et al. Early detection of thrombin activity in neuroinflammatory disease. Ann Neurol 
75, 303–308 (2014). [PubMed: 24740641] 
28. Haider L et al. Oxidative damage in multiple sclerosis lesions. Brain 134, 1914–1924 (2011). 
[PubMed: 21653539] 
29. Heneka MT et al. Neuroinflammation in Alzheimer’s disease. Lancet Neurol 14, 388–405 (2015). 
[PubMed: 25792098] 
30. DeKosky ST & Scheff SW Synapse loss in frontal cortex biopsies in Alzheimer’s disease: 
correlation with cognitive severity. Ann Neurol 27, 457–464 (1990). [PubMed: 2360787] 
31. Zhang B et al. Integrated systems approach identifies genetic nodes and networks in late-onset 
Alzheimer’s disease. Cell 153, 707–720 (2013). [PubMed: 23622250] 
32. Shoeb M & Fang MC Assessing bleeding risk in patients taking anticoagulants. J Thromb 
Thrombolysis 35, 312–319 (2013). [PubMed: 23479259] 
33. Mocsai A et al. Integrin signaling in neutrophils and macrophages uses adaptors containing 
immunoreceptor tyrosine-based activation motifs. Nat Immunol 7, 1326–1333 (2006). [PubMed: 
17086186] 
34. Bedard K & Krause KH The NOX family of ROS-generating NADPH oxidases: physiology and 
pathophysiology. Physiol Rev 87, 245–313 (2007). [PubMed: 17237347] 
Ryu et al. Page 19
Nat Immunol. Author manuscript; available in PMC 2019 April 15.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
35. Turnbull IR & Colonna M Activating and inhibitory functions of DAP12. Nat Rev Immunol 7, 
155–161 (2007). [PubMed: 17220916] 
36. Park L et al. Scavenger receptor CD36 is essential for the cerebrovascular oxidative stress and 
neurovascular dysfunction induced by amyloid-beta. Proc Natl Acad Sci U S A 108, 5063–5068 
(2011). [PubMed: 21383152] 
37. Cummings J Lessons Learned from Alzheimer Disease: Clinical Trials with Negative Outcomes. 
Clin Transl Sci 11, 147–152 (2018). [PubMed: 28767185] 
38. Vemuri P et al. Vascular and amyloid pathologies are independent predictors of cognitive decline in 
normal elderly. Brain 138, 761–771 (2015). [PubMed: 25595145] 
39. Rabin JS et al. Interactive Associations of Vascular Risk and beta-Amyloid Burden With Cognitive 
Decline in Clinically Normal Elderly Individuals: Findings From the Harvard Aging Brain Study. 
JAMA Neurol (2018).
40. Miron VE et al. M2 microglia and macrophages drive oligodendrocyte differentiation during CNS 
remyelination. Nat Neurosci 16, 1211–1218 (2013). [PubMed: 23872599] 
41. Petersen MA et al. Fibrinogen Activates BMP Signaling in Oligodendrocyte Progenitor Cells and 
Inhibits Remyelination after Vascular Damage. Neuron 96, 1003–1012 e1007 (2017). [PubMed: 
29103804] 
42. Oka A, Belliveau MJ, Rosenberg PA & Volpe JJ Vulnerability of oligodendroglia to glutamate: 
pharmacology, mechanisms, and prevention. J Neurosci 13, 1441–1453 (1993). [PubMed: 
8096541] 
43. Butovsky O et al. Identification of a unique TGF-beta-dependent molecular and functional 
signature in microglia. Nat Neurosci 17, 131–143 (2014). [PubMed: 24316888] 
44. Ajami B et al. Single-cell mass cytometry reveals distinct populations of brain myeloid cells in 
mouse neuroinflammation and neurodegeneration models. Nat Neurosci 21, 541–551 (2018). 
[PubMed: 29507414] 
45. Keren-Shaul H et al. A Unique Microglia Type Associated with Restricting Development of 
Alzheimer’s Disease. Cell 169, 1276–1290 (2017). [PubMed: 28602351] 
46. Mrdjen D et al. High-Dimensional Single-Cell Mapping of Central Nervous System Immune Cells 
Reveals Distinct Myeloid Subsets in Health, Aging, and Disease. Immunity 48, 380–395 (2018). 
[PubMed: 29426702] 
47. Suh TT et al. Resolution of spontaneous bleeding events but failure of pregnancy in fibrinogen-
deficient mice. Genes Dev 9, 2020–2033 (1995). [PubMed: 7649481] 
48. Flick MJ et al. Leukocyte engagement of fibrin(ogen) via the integrin receptor alphaMbeta2/Mac-1 
is critical for host inflammatory response in vivo. J Clin Invest 113, 1596–1606 (2004). [PubMed: 
15173886] 
49. Lak M, Keihani M, Elahi F, Peyvandi F & Mannucci PM Bleeding and thrombosis in 55 patients 
with inherited afibrinogenaemia. Br J Haematol 107, 204–206 (1999). [PubMed: 10520042] 
50. Bugge TH et al. Loss of fibrinogen rescues mice from the pleiotropic effects of plasminogen 
deficiency. Cell 87, 709–719 (1996). [PubMed: 8929539] 
51. Akassoglou K, Yu W-M, Akpinar P & Strickland S Fibrin inhibits peripheral nerve regeneration by 
arresting Schwann cell differentiation. Neuron 33, 861–875 (2002). [PubMed: 11906694] 
52. Koseki-Kuno S, Yamakawa M, Dickneite G & Ichinose A Factor XIII A subunit-deficient mice 
developed severe uterine bleeding events and subsequent spontaneous miscarriages. Blood 102, 
4410–4412 (2003). [PubMed: 12933578] 
53. Chen R & Doolittle RF - cross-linking sites in human and bovine fibrin. Biochemistry 10, 4487–
4491 (1971). [PubMed: 5168975] 
54. Aleman MM et al. Factor XIII activity mediates red blood cell retention in venous thrombi. J Clin 
Invest 124, 3590–3600 (2014). [PubMed: 24983320] 
55. Jung S et al. Analysis of fractalkine receptor CX(3)CR1 function by targeted deletion and green 
fluorescent protein reporter gene insertion. Mol Cell Biol 20, 4106–4114 (2000). [PubMed: 
10805752] 
56. Feng G et al. Imaging neuronal subsets in transgenic mice expressing multiple spectral variants of 
GFP. Neuron 28, 41–51 (2000). [PubMed: 11086982] 
Ryu et al. Page 20
Nat Immunol. Author manuscript; available in PMC 2019 April 15.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
57. Oakley H et al. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in 
transgenic mice with five familial Alzheimer’s disease mutations: potential factors in amyloid 
plaque formation. J Neurosci 26, 10129–10140 (2006). [PubMed: 17021169] 
58. Jackson SH, Gallin JI & Holland SM The p47phox mouse knock-out model of chronic 
granulomatous disease. J Exp Med 182, 751–758 (1995). [PubMed: 7650482] 
59. Saederup N et al. Selective chemokine receptor usage by central nervous system myeloid cells in 
CCR2-red fluorescent protein knock-in mice. PLoS One 5, e13693 (2010). [PubMed: 21060874] 
60. Jensen MR et al. Structural Basis for Simvastatin Competitive Antagonism of Complement 
Receptor 3. J Biol Chem 291, 16963–16976 (2016). [PubMed: 27339893] 
61. Abid MR, Spokes KC, Shih SC & Aird WC NADPH oxidase activity selectively modulates 
vascular endothelial growth factor signaling pathways. J Biol Chem 282, 35373–35385 (2007). 
[PubMed: 17908694] 
62. Davalos D et al. Fibrinogen-induced perivascular microglial clustering is required for the 
development of axonal damage in neuroinflammation. Nat Commun 3, 1227 (2012). [PubMed: 
23187627] 
63. Klunk WE et al. Imaging Abeta plaques in living transgenic mice with multiphoton microscopy 
and methoxy-X04, a systemically administered Congo red derivative. J Neuropathol Exp Neurol 
61, 797–805 (2002). [PubMed: 12230326] 
64. Gentleman RC et al. Bioconductor: open software development for computational biology and 
bioinformatics. Genome Biol 5, R80 (2004). [PubMed: 15461798] 
Ryu et al. Page 21
Nat Immunol. Author manuscript; available in PMC 2019 April 15.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Fig. 1 │. Generation and characterization of monoclonal antibody 5B8 targeting the γ377–395 
fibrin epitope.
a, Structural map of cryptic epitope γ377–395 in the γC-domain of fibrinogen. The γ377–395 
epitope (red) includes a core β-strand and portion of the fibrin γC-domain’s C-terminal loop 
and binds to the CD11b I-domain. b, Binding affinity of 5B8 to γ377–395 measured by 
ELISA. Data are mean ± s.e.m. of 4 independent experiments. c, Comparison of 5B8 
binding to fibrin and fibrinogen by ELISA. Data are mean ± s.e.m. of 3 independent 
experiments. d, 5B8 competition with the CD11b I-domain for binding to fibrin by 
competitive ELISA. Data shown from one experiment. e, Microglia stimulated with fibrin in 
the presence of 5B8 (10, 20, and 40 μg/ml). Representative images are shown from 
unstimulated, and fibrin-treated microglia in the absence or presence of 40 μg/ml 5B8. Scale 
bar, 10 μm. Quantification of microglia activation (increased cell size) at 48 h after treatment 
is shown. Data are mean ± s.e.m. from 4 independent experiments (untreated, fibrin, fibrin 
+ 40 μg/ml 5B8) analyzed with manual and automated quantification with similar results. 
****P < 0.0001 by one-way analysis of variance (ANOVA) with Sidak’s multiple 
comparisons test. f, In vitro fibrin polymerization was examined in the presence of 
fibrinogen (FN) alone or with 5B8, IgG2b, or GPRP. Data are representative of two 
independent experiments with similar results. g, aPTT assay was performed in human 
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plasma in the presence of 5B8, IgG2b, or GPRP. Data are representative of two independent 
experiments with similar results. h, In vivo clotting times of blood from 5B8-injected mice 
and uninjected controls. Data are mean ± s.e.m.; n = 8 mice per treatment. P = 0.7768 (two-
tailed Mann-Whitney test); n.s., not significant.
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Fig. 2 │. Gene expression changes by 5B8 treatment of fibrin-stimulated BMDMs.
a, MA plot of whole-genome microarray analysis of 5B8- vs. IgG2b-treated BMDMs 6 h 
after fibrin stimulation. Colors indicate genes whose expression was significantly increased 
(orange) or decreased (purple) by 5B8; the remaining genes are in gray. Data are from 3 
independent experiments. Linear models were fitted for each gene using the Bioconductor 
‘limma’ package in R. Moderated t-statistics, fold change and the associated P values were 
calculated for each gene (two-tailed, raw P < 0.001). b, The top 10 biological processes 
relevant to 5B8-reduced innate/adaptive immune transcripts in BMDMs were identified by 
GO-Elite analysis (Z score >2.0, P < 0.05) c, Heat map of the top 20 transcripts that were 
significantly downregulated after 5B8 treatment of fibrin-stimulated BMDMs. Whole-
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genome microarray data from 3 independent experiments. d, Relative expression of 
transcripts of proinflammatory genes Ccl24, Tnfsf18, Il12b, Cxcl3, and Ifng in fibrin-
stimulated BMDMs treated with 5B8 or IgG2b, measured by qRT-PCR. Y-axis indicates 
log2 value of relative fold changes in qRT-PCR results. Data are mean ± s.e.m. from 3 
independent experiments. *** P = 0.0001 (Ccl24), ** P = 0.0052 (Tnfsf18), *** P = 0.0010 
(Il12b), ** P = 0.0050 (Cxcl3), and ** P = 0.0015 (Ifng) by unpaired two-tailed t-test with 
Welch’s correction. e, 5B8 had no effect on LPS-induced gene expression in BMDMs 
analyzed by qRT-PCR. Y-axis indicates log2 value of relative fold changes in qRT-PCR 
results. Data are mean ± s.e.m. from 3 independent experiments. No significant difference 
by unpaired two-tailed t-test with Welch’s correction.
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Fig. 3 │. 5B8 blocks fibrin-induced ROS production and axonal damage.
a, Heat map of significantly differentially expressed ROS-related genes in fibrin-induced 
microglia and BMDMs (|log2 fold change| > 0.585 and FDR < 0.05; two-tailed moderated t-
test). b, Immunoblot for gp91phox and p-p40phox in BMDMs stimulated with fibrin as 
indicated in the presence of 5B8 or IgG2b. Representative cropped blot images from 3 
independent experiments are shown. Full blots are included in Supplementary Fig. 9. c, 
NADPH oxidase activity in 12 h fibrin-stimulated BMDMs in the presence of 5B8 or IgG2b. 
Data are mean ± s.e.m. of 3 independent experiments. RLU, relative chemiluminescent light 
units. ** P = 0.0015 and *** P = 0.0001 by one-way ANOVA with Tukey’s multiple 
comparisons test. d, ROS production by fibrin-stimulated BMDMs detected with 
dihydroethidium (DHE, red). Scale bar, 10 μm. Data are representative of three independent 
experiments with similar results. e, Quantification of ROS production by DHE in BMDMs 
(left) and human PBMC-derived macrophages (right) 48 h after fibrin stimulation in the 
presence of 5B8 or IgG2b. Data are mean ± s.e.m. of 4 (left graph) and 2 (right graph) 
independent experiments. A.U., arbitrary units. ** P = 0.0033, **** P <0.0001 (mouse 
BMDMs) by one-way ANOVA with Bonferroni multiple comparisons test. f, ROS 
production 24 h after fibrin stimulation in BMDMs isolated from WT and p47phox–/– mice. 
Data are mean ± s.e.m. of n = 4 mice per group. A.U. * P = 0.0204, ** P = 0.0040 by two-
way ANOVA with Sidak’s multiple comparisons test. n.s., not significant. g, ROS 
production measured by DHE in murine BMDMs 24 h after fibrin stimulation in the 
presence of apocynin. Data are mean ± s.e.m. of 3 independent experiments. A.U.-- **** P 
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< 0.0001 by one-way ANOVA with Tukey’s multiple comparisons test. h, MAP-2+ (upper 
panel) and synapsin-RFP (lower panel) cortical neurons co-cultured with unstimulated or 
fibrin-stimulated BMDMs in the presence of 5B8 or IgG2b. Scale bars, 50 μm (top panels) 
and 30 μm (bottom panels). Quantification of MAP-2+ neurites (top) and synapsin-RFP+ 
neurites (bottom). Data are mean ± s.e.m. from 4 independent experiments * P = 0.0385 
(unstimulated vs Fibrin+IgG2b, top), * P = 0.0370 (Fibrin+IgG2b vs Fibrin+5B8, top); * P = 
0.0168 (Fibrin+IgG2b vs Fibrin+5B8, bottom) by one-way ANOVA with Bonferroni 
multiple comparisons test.
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Fig. 4 │. 5B8 suppresses EAE and engages fibrin target.
a, Reduction of clinical signs after 5B8 administration in four EAE models. Prophylactic 
administration of 5B8 or IgG2b isotype control in PLP139–151, MOG35–55, and adoptive 
transfer TH1 EAE (* P < 0.05, ** P < 0.01, linear mixed effects model with two-tailed 
permutation test). Mice were each given 800 μg of either 5B8 or isotype-control IgG2b 
every two days from day 0. Data are mean ± s.e.m. from PLP139–151 (n = 16 IgG2b and n = 
16 5B8), MOG35–55 (n = 11 IgG2b and n = 12 5B8), and TH1 EAE (n = 15 IgG2b and n = 
24 5B8) b, Therapeutic administration of 5B8 or IgG2b isotype control in PLP139–151 EAE 
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after peak of disease (* P < 0.05, ** P < 0.01, *** P < 0.001, linear mixed effects model 
with two-tailed permutation test). For therapeutic treatment, antibodies were injected every 
two days starting at the peak of the initial paralytic episode. Data are mean ± s.e.m. from 
PLP139–151 EAE (n = 10 IgG2b and n = 10 5B8). c, Effect of 5B8 treatment on the 
percentage of paralyzed mice (defined as partial or complete hindlimb paralysis, score >2.5) 
in three EAE groups. d, Target engagement of i.p. injected biotinylated 5B8 in MOG35–55 
EAE mice and healthy non-immunized control mice. Confocal microscopy of spinal cord 
sections from MOG35–55 EAE mice shows the spatial correlation (yellow) between 
biotinylated 5B8, detected with Cy3-streptavidin (red), and fibrin deposition, detected with a 
fibrin(ogen) antibody (green), in MOG35–55 EAE mice. Representative images are shown 
from n = 3 mice per group. Scale bar, 200 μm.
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Fig. 5 │. 5B8 inhibits microglial activation, monocyte recruitment, and axonal damage in EAE.
a, Spinal cord images of 5B8- or IgG2b-treated MOG35–55 EAE Cx3cr1GFP/+Ccr2RFP/+ 
mice. Scale bar, 500 μm. Quantification of Cx3cr1+ microglia (GFP, green) and Ccr2+ 
macrophages (RFP, red). Data are mean ± s.e.m.; n = 4 mice per treatment. * P = 0.0495 
(GFP), * P = 0.0286 (RFP), by two-tailed Mann-Whitney test. b, SMI-32 immunoreactivity 
indicative of axonal damage in spinal cords of 5B8- or IgG2b-treated PLP139–151 EAE mice. 
Scale bar, 200 μm. Dotted lines indicate spinal cord dorsal column white matter. 
Quantification of SMI-32 immunoreactivity. Data are mean ± s.e.m.; n = 8 mice per group. 
*** P = 0.0002 , two-tailed Mann-Whitney test. c, ROS detection in the spinal cord with 
DHE of 5B8- or IgG2b-treated PLP139–151 EAE mice. Scale bar, 100 μm. Quantification of 
DHE. Data are mean ± s.e.m.; n = 8 IgG2b and n = 7 5B8. * P = 0.0140 by two-tailed Mann-
Whitney test.
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Fig. 6 │. In vivo imaging of fibrinogen leakage in 5XFAD mice.
a, Fluorescent Aβ probe methoxy-X04-positive amyloid plaque in a cortical section from a 
3-month-old 5XFAD mouse co-labeled for fibrinogen (red) and CD11b (green). Scale bar: 
20 μm. n = 4 mice. Representative images are shown. b, In vivo two-photon imaging of 
cortex from Thy1-YFP:5XFAD mice at 11 months of age shows Alexa594-conjugated 
fibrinogen (administered intravenously) (red), a methoxy-X04-positive Aβ plaque (blue), 
and dystrophic neurites (green, swollen green structures). Arrowheads indicate fibrinogen 
(red) surrounding a Aβ plaque (blue) at areas of neuritic loss. Arrows indicate fibrinogen 
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extravasation at areas of dystrophic neurites (yellow) in proximity to a plaque (blue). Scale 
bars: 10 μm. (n = 4 Thy1-YFP:5XFAD mice and n = 2 Thy1-YFP mice. Representative 
images are shown. c, 5B8 in vivo target engagement in the brain of 5XFAD mice. Brain 
sections of 5XFAD i.p.-injected with biotinylated 5B8 were stained with Cy3-streptavidin 
(red), anti-fibrinogen (green), and methoxy-X04-positive Aβ plaque (blue). Orthogonal 
views of the y/z and x/z planes show localization of fibrinogen and 5B8 antibody around 
amyloid plaques. Scale bar, 10 μm. n =3 mice Representative images are shown.
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Fig. 7 │. 5B8 protects against neurodegeneration and inflammatory responses in 5XFAD mice.
a, Schematic representation of 5B8 administration after appearance of plaques and microglia 
activation in 5XFAD mice (800 μg i.p. every other day for 2 months starting at 3.5 months of 
age). b, ChAT-positive cholinergic neurons in the medial septum of non-transgenic littermate 
control (WT), 5XFAD mice treated with IgG2b or 5B8. Scale bars 80 μm. Quantification of 
ChAT+ neurons. Data are mean ± s.e.m.; n = 3 WT, n = 7 IgG2b-treated and n = 8 5B8-
treated 5XFAD mice. * P = 0.0211 (WT vs IgG2b), * P = 0.0157 (IgG2b vs 5B8) by 
Kruskal–Wallis with Dunn’s multiple comparisons test. c, Iba-1+ cells (green) around 
Methoxy-X04+ plaques (blue) in the cortex of 5XFAD mice treated with IgG2b or 5B8. 
Quantification of plaque-associated Iba-1+ microglia. Scale bar: 50 μm. Data are mean ± 
s.e.m.; n = 7 IgG2b-treated and n = 9 5B8-treated 5XFAD mice. * P = 0.0337 by two-tailed 
Mann-Whitney test. d, Affymetrix microarray gene expression analysis in the cortex of 5B8- 
or IgG2b-treated 5XFAD mice. Linear models were fitted for each gene using the 
Bioconductor ‘limma’ package in R. Moderated t-statistics, fold change and the associated P 
values were calculated for each gene (two-tailed, raw P < 0.05). Heatmap of select genes 
with differential expression patterns from GO terms were identified by GO-Elite analysis.
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Fig. 8 │. 5B8 suppresses the complement/TYROBP microglial module in 5XFAD mice.
a, Co-expression analysis revealed 5B8-downregulated genes to be densely interconnected, 
with Tyrobp forming a major hub. Blue shading indicates the level of reduction of gene 
expression by 5B8 compared to IgG2b treatment. The thickness of the red border around the 
circles indicates the statistical significance of the differential expression, and the size of the 
circles indicates the number of connected genes in this co-expression network. 
Downregulated genes of interest were selected from those with log2 fold change of −0.5 or 
less and raw p-value < 0.05 (two-tailed moderated t-test). b, Mouse model of the human AD 
TYROBP network with data overlay of the 5B8-downregulated genes in the 5XFAD mice. 
Yellow-Blue gradient fill color indicates differential expression and red border thickness 
indicates significance of P < 0.05 (two-tailed moderated t-test).
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